Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Research & Development (2020 - 2025)

Historic Research & Development for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $2.8 million.

  • Gain Therapeutics' Research & Development rose 868.85% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year decrease of 2386.84%. This contributed to the annual value of $10.8 million for FY2024, which is 633.26% down from last year.
  • Per Gain Therapeutics' latest filing, its Research & Development stood at $2.8 million for Q3 2025, which was up 868.85% from $2.8 million recorded in Q2 2025.
  • Gain Therapeutics' Research & Development's 5-year high stood at $4.4 million during Q2 2024, with a 5-year trough of $1.2 million in Q4 2024.
  • For the 5-year period, Gain Therapeutics' Research & Development averaged around $2.4 million, with its median value being $2.4 million (2023).
  • In the last 5 years, Gain Therapeutics' Research & Development skyrocketed by 47940.16% in 2021 and then plummeted by 4840.74% in 2024.
  • Gain Therapeutics' Research & Development (Quarter) stood at $1.5 million in 2021, then surged by 54.42% to $2.3 million in 2022, then increased by 4.4% to $2.4 million in 2023, then crashed by 48.41% to $1.2 million in 2024, then soared by 132.65% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $2.8 million for Q2 2025, and $2.3 million during Q1 2025.